{
  "@context": "aku-v2",
  "@type": "treatment",
  "@id": "vasc:lm:treatment",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:21:00.000Z",
    "updated": "2026-01-07T03:21:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.90,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vascular-malformations",
    "type": "treatment-modality",
    "difficulty": "advanced",
    "importance": "high"
  },
  "content": {
    "title": "Lymphatic Malformation Treatment",
    "description": "Treatment approaches for lymphatic malformations",
    "key_concepts": [
      {
        "concept": "Sclerotherapy",
        "details": "First-line for macrocystic LM; OK-432 (picibanil), doxycycline, bleomycin, ethanol"
      },
      {
        "concept": "Surgical Excision",
        "details": "Consider for localized lesions or sclerotherapy failures; complete excision difficult"
      },
      {
        "concept": "Sirolimus",
        "details": "mTOR inhibitor showing efficacy for complex lymphatic anomalies"
      },
      {
        "concept": "Observation",
        "details": "May be appropriate for asymptomatic small lesions; spontaneous regression rare"
      }
    ],
    "clinical_significance": "Macrocystic LMs respond better to treatment than microcystic forms"
  },
  "provenance": {
    "primary_sources": ["Adams DM et al. Blood 2016"]
  }
}
